Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: A randomized controlled trial

Evdokia Anagnostou, Latha Soorya, William Chaplin, Jennifer Bartz, Danielle Halpern, Stacey Wasserman, A. Ting Wang, Lauren Pepa, Nadia Tanel, Azadeh Kushki, Eric Hollander

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

Background: There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors. Methods. This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 ± 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale - compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses. Results: Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire - emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported. Conclusions: This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted. Trial registration. NCT00490802.

Original languageEnglish (US)
Article number16
JournalMolecular Autism
Volume3
Issue number1
DOIs
StatePublished - 2012

Fingerprint

Oxytocin
Randomized Controlled Trials
Cognition
Placebos
Quality of Life
Reading
Therapeutics
Likelihood Functions
Intranasal Administration
Genetic Association Studies
Therapeutic Uses
Autism Spectrum Disorder
Emotions
Animal Models
Regression Analysis
Outcome Assessment (Health Care)
Safety

Keywords

  • Adults
  • Autism
  • Clinical trial
  • Oxytocin
  • Social cognition

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental Neuroscience
  • Developmental Biology
  • Molecular Biology

Cite this

Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders : A randomized controlled trial. / Anagnostou, Evdokia; Soorya, Latha; Chaplin, William; Bartz, Jennifer; Halpern, Danielle; Wasserman, Stacey; Wang, A. Ting; Pepa, Lauren; Tanel, Nadia; Kushki, Azadeh; Hollander, Eric.

In: Molecular Autism, Vol. 3, No. 1, 16, 2012.

Research output: Contribution to journalArticle

Anagnostou, E, Soorya, L, Chaplin, W, Bartz, J, Halpern, D, Wasserman, S, Wang, AT, Pepa, L, Tanel, N, Kushki, A & Hollander, E 2012, 'Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: A randomized controlled trial', Molecular Autism, vol. 3, no. 1, 16. https://doi.org/10.1186/2040-2392-3-16
Anagnostou, Evdokia ; Soorya, Latha ; Chaplin, William ; Bartz, Jennifer ; Halpern, Danielle ; Wasserman, Stacey ; Wang, A. Ting ; Pepa, Lauren ; Tanel, Nadia ; Kushki, Azadeh ; Hollander, Eric. / Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders : A randomized controlled trial. In: Molecular Autism. 2012 ; Vol. 3, No. 1.
@article{0f3cbca89bb44641b85063595bf27bdb,
title = "Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: A randomized controlled trial",
abstract = "Background: There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors. Methods. This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 ± 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale - compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses. Results: Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire - emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported. Conclusions: This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted. Trial registration. NCT00490802.",
keywords = "Adults, Autism, Clinical trial, Oxytocin, Social cognition",
author = "Evdokia Anagnostou and Latha Soorya and William Chaplin and Jennifer Bartz and Danielle Halpern and Stacey Wasserman and Wang, {A. Ting} and Lauren Pepa and Nadia Tanel and Azadeh Kushki and Eric Hollander",
year = "2012",
doi = "10.1186/2040-2392-3-16",
language = "English (US)",
volume = "3",
journal = "Molecular Autism",
issn = "2040-2392",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders

T2 - A randomized controlled trial

AU - Anagnostou, Evdokia

AU - Soorya, Latha

AU - Chaplin, William

AU - Bartz, Jennifer

AU - Halpern, Danielle

AU - Wasserman, Stacey

AU - Wang, A. Ting

AU - Pepa, Lauren

AU - Tanel, Nadia

AU - Kushki, Azadeh

AU - Hollander, Eric

PY - 2012

Y1 - 2012

N2 - Background: There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors. Methods. This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 ± 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale - compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses. Results: Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire - emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported. Conclusions: This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted. Trial registration. NCT00490802.

AB - Background: There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors. Methods. This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 ± 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale - compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses. Results: Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire - emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported. Conclusions: This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted. Trial registration. NCT00490802.

KW - Adults

KW - Autism

KW - Clinical trial

KW - Oxytocin

KW - Social cognition

UR - http://www.scopus.com/inward/record.url?scp=84872107494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872107494&partnerID=8YFLogxK

U2 - 10.1186/2040-2392-3-16

DO - 10.1186/2040-2392-3-16

M3 - Article

C2 - 23216716

AN - SCOPUS:84872107494

VL - 3

JO - Molecular Autism

JF - Molecular Autism

SN - 2040-2392

IS - 1

M1 - 16

ER -